Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + finerenone
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dapagliflozin + finerenone is a combination regimen consisting of a sodium-glucose cotransporter-2 (SGLT2) inhibitor and a non-steroidal mineralocorticoid receptor antagonist (MRA). Dapagliflozin works by inhibiting glucose reabsorption in the proximal tubule of the kidney, leading to glucosuria and osmotic diuresis, which reduces intraglomerular pressure. Finerenone selectively blocks the mineralocorticoid receptor, thereby inhibiting inflammation and fibrosis in the heart and kidneys. This combination is being investigated for its potential additive or synergistic effects in reducing albuminuria and slowing the progression of chronic kidney disease in patients with type 2 diabetes (diabetic nephropathy). The regimen is currently being evaluated in investigator-initiated clinical trials to determine if the dual blockade of these pathways provides superior renoprotection compared to monotherapy.
- Other names
- dapagliflozin-finerenone combination
02
Targets
AR (Adrenergic receptors)PR (Progesterone receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A1 (Sodium Glucose Cotransporter 1)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on dapagliflozin + finerenone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + finerenone.